Hims & Hers Health, Inc. (HIMS)
| Market Cap | 6.43B -56.2% |
| Revenue (ttm) | 2.37B +32.8% |
| Net Income | -13.24M |
| EPS | -0.06 |
| Shares Out | 231.46M |
| PE Ratio | n/a |
| Forward PE | 32.51 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 12,585,138 |
| Open | 27.48 |
| Previous Close | 27.04 |
| Day's Range | 26.86 - 28.94 |
| 52-Week Range | 13.74 - 70.43 |
| Beta | 2.43 |
| Analysts | Hold |
| Price Target | 29.23 (+5.26%) |
| Earnings Date | Aug 10, 2026 |
About HIMS
Hims & Hers Health, Inc. operates as a consumer-first health and wellness platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, Canada, Germany, the Republic of Ireland, France, Spain, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers. It also provides personalized health and wellness products; over-the-counter drug and de... [Read more]
Financial Performance
In 2025, Hims & Hers Health's revenue was $2.35 billion, an increase of 59.00% compared to the previous year's $1.48 billion. Earnings were $128.37 million, an increase of 1.85%.
Financial StatementsAnalyst Summary
According to 15 analysts, the average rating for HIMS stock is "Hold." The 12-month stock price target is $29.23, which is an increase of 5.26% from the latest price.
News
HIMS Investors Have Opportunity to Join Hims & Hers Health, Inc. Fraud Investigation with SBS Law
LOS ANGELES--(BUSINESS WIRE)---- $HIMS--HIMS Investors Have Opportunity to Join Hims & Hers Health, Inc. Fraud Investigation with SBS Law.
Hims & Hers Stock Jumps on Vow to ‘Vigorously’ Defend Against FTC’s ‘Baseless Claims’
Shares in telehealth provider Hims & Hers Health ($HIMS) popped by more than 5% on Thursday morning after plunging by almost 15% the previous day. This came even after the…
FTC sues Hims & Hers for allegedly sharing patients' medical data with advertisers Meta and Snap
The Federal Trade Commission is suing healthcare giant Hims & Hers for allegedly sharing its customers' medical and healthcare information with advertisers and tech giants, like Meta and Snap, as well...
Hims & Hers sent users' health data to social media giants despite promising privacy, bombshell FTC lawsuit claims
Hims & Hers stock added to losses after the news and was trading down around 12%.
Wednesday's Final Takeaways: Fed Holds Rates & HIMS Lawsuit
Marley Kayden talks about the Fed's decision to leave interest rates unchanged despite dissents from three of the FOMC members. She also discusses the sell-off in Hims & Hers (HIMS) after FTC filed a ...
Hims and Hers shares fall 10% as FTC sues company over data, billing practices
The FTC alleged Hims & Hers shared sensitive user health information with advertisers including Meta and Snap through tracking technologies without proper consent. Regulators also accuse the telehealt...
FTC Claims Hims & Hers Charged Patients Without Consent And Shared Health Data With Big Tech
2.6 million. That's how many people subscribe to Him & Hers for personal health, skin care, hair loss treatments and weight-loss management, according to the company's first quarter results, up 9% yea...
Hims & Hers Responds to FTC Lawsuit
SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (NYSE: HIMS) responded to the lawsuit filed today by the Federal Trade Commission (FTC): This lawsuit disregards substantial evidence we provid...
Hims & Hers Health Stock Sinks on Privacy, Deceptive Billing Lawsuit
Shares in telehealth provider Hims & Hers ($HIMS) tumbled about 12% on Wednesday afternoon. This came as the U.S. consumer protection watchdog dragged the company to court. The case relates…
US FTC suing Hims & Hers for sending user health info to Meta, Snap
The U.S. Federal Trade Commission is suing Hims & Hers alleging the telehealth platform shared users' health data with online advertisers despite promising privacy and engaged in deceptive billing a...
Is Today’s Dip a Buying Opportunity for Hims & Hers Health (HIMS) Stock?
Hims & Hers Health stock fell hard on Friday and investors might be wondering if now is the time to buy the shares.
Hims & Hers falls -10.3%
Hims & Hers (HIMS) is down -10.3%, or -$3.38 to $29.36.
Canaccord Expects Hims & Hers Stock (HIMS) to Outperform ‘Major Indices by Several Hundred Basis Points.’ Here’s Why
Hims & Hers Health ($HIMS) stock rose 3.4% on Thursday after the Pharmacy Compounding Advisory Committee (PCAC) of the U.S. Food and Drug Administration (FDA) voted to place BPC-157, a widely…
Here’s Why Hims & Hers Stock Soared 13% Today – July 23, 2026
Hims & Hers Health ($HIMS) surged as much as 13% on Thursday after the Food and Drug Administration (FDA) advisory panel voted to recommend loosening restrictions on a popular peptide…
Hims & Hers stands to gain if the FDA loosens restrictions on peptides
Hims & Hers Health is set to tap what analysts estimate could be a multi-billion-dollar market for peptides if U.S. regulators loosen manufacturing restrictions.
Hims & Hers Chief Accounting Officer, Irene Becklund, Announces Departure from the Company
SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (NYSE: HIMS), the leading health and wellness platform, today announced its Chief Accounting Officer, Irene Becklund will depart the company af...
Hims & Hers to Announce Second Quarter 2026 Financial Results on August 10, 2026
SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (“Hims & Hers”, NYSE: HIMS), the leading health and wellness platform, today announced that it will report second quarter 2026 financial result...
Amplify Online Retail ETF Rides a Summer Surge in Performance
The Amplify Online Retail ETF (IBUY) has rallied over the past month, signaling a robust appetite for online consumer discretionary spending despite persistent macroeconomic headwinds. Outsized gains ...
Hims & Hers stock jumps as Canaccord lifts target price ahead of FDA review
Hims & Hers Health shares (HIMS) surged 9% on Wednesday after Canaccord Genuity raised its price target on the telehealth company, citing improving sales trends, momentum in its weight-loss business, ...
Hims' obesity drug business may get boost as employers drop coverage
Telehealth provider Hims and Hers Health may get a boost next year from employers dropping coverage of weight-loss drugs like Novo Nordisk's Wegovy and Eli Lilly's Zepbound and Foundayo to rein in co...
Living Longer Is Big Business. These Stocks Will Benefit.
TD Cowen analysts estimate that the total addressable market for longevity healthcare exceeds $250 billion.
Hims & Hers Health Transcript: AGM 2026
The meeting covered director elections, auditor ratification, and executive compensation, all of which were approved by majority or plurality vote. Stockholders could submit questions virtually, with responses to follow after the meeting.
Hims & Hers Names Dr. Anant Vinjamoori as Chief Medical Officer of Hims
SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (NYSE: HIMS), the leading health and wellness platform, today announced Dr. Anant Vinjamoori is joining as the Chief Medical Officer of the Him...
Hims & Hers Health Transcript: 2026 Evercore Global TMT Conference
Ambitious 2030 targets are set, driven by global expansion, specialty growth, and technology investments. Recent acquisitions and partnerships, especially with Eucalyptus and Novo Nordisk, accelerate international reach and deepen consumer engagement. AI and data are central to platform differentiation and operational efficiency.
Hims & Hers Completes Acquisition of Eucalyptus, Accelerating Its Push to Transform Healthcare for Canadians
TORONTO--(BUSINESS WIRE)--Hims & Hers Health, Inc. today announced the completion of its acquisition of Eucalyptus, the parent company of Juniper, marking the latest in a series of significant company...